Pamela New1. 1. Department of Neurosurgery/Neuro-oncology, Baylor College of Medicine, Houston, TX 77030, USA. pnew@bcm.tmc.edu
Abstract
BACKGROUND: High-grade glioma remains one of the most difficult cancers to treat. Recent studies in oncology have identified a role of the ubiquitous enzyme, cyclooxygenase (Cox), especially cyclooxygenase-2 (COX-2) in cell proliferation, and its inhibition in cancer control, apoptosis, as well as synergy with other forms of therapy. The inhibitors of the Cox enzyme are well known as members of the nonsteroidal anti-inflammatory drug (NSAID) class of pharmaceuticals. METHODS: In vitro and in vivo studies of different cancers expressing COX-2, including glioma studies, along with the few clinical trials that have been reported are reviewed to specifically identify the actions of these agents. RESULTS: The anticancer effect of the COX-2 inhibitors may occur irrelevant of COX-2 expression, and it appears to be drug-specific, as well as dose-specific in different cancers. In combination with chemotherapeutic agents, the COX-2 inhibitors may have an additive, synergistic, or inhibitory effect on tumor growth. CONCLUSIONS: As evaluations of this class of drugs begin in glioma, in vitro and in vivo data should be acquired to accurately predict which compounds will have an effect in controlling tumor growth and at which doses these should be used. The actual expression and inhibition of COX-2 may not always be relevant to the effects on tumor growth.
BACKGROUND: High-grade glioma remains one of the most difficult cancers to treat. Recent studies in oncology have identified a role of the ubiquitous enzyme, cyclooxygenase (Cox), especially cyclooxygenase-2 (COX-2) in cell proliferation, and its inhibition in cancer control, apoptosis, as well as synergy with other forms of therapy. The inhibitors of the Cox enzyme are well known as members of the nonsteroidal anti-inflammatory drug (NSAID) class of pharmaceuticals. METHODS: In vitro and in vivo studies of different cancers expressing COX-2, including glioma studies, along with the few clinical trials that have been reported are reviewed to specifically identify the actions of these agents. RESULTS: The anticancer effect of the COX-2 inhibitors may occur irrelevant of COX-2 expression, and it appears to be drug-specific, as well as dose-specific in different cancers. In combination with chemotherapeutic agents, the COX-2 inhibitors may have an additive, synergistic, or inhibitory effect on tumor growth. CONCLUSIONS: As evaluations of this class of drugs begin in glioma, in vitro and in vivo data should be acquired to accurately predict which compounds will have an effect in controlling tumor growth and at which doses these should be used. The actual expression and inhibition of COX-2 may not always be relevant to the effects on tumor growth.
Authors: Peter Sminia; T Rianne Stoter; Paul van der Valk; Paula H M Elkhuizen; Thea M Tadema; Gitta K Kuipers; W Peter Vandertop; M Vincent M Lafleur; Ben J Slotman Journal: J Cancer Res Clin Oncol Date: 2005-10-20 Impact factor: 4.553
Authors: Dan Zhang; Xiaoming Hu; Li Qian; Belinda Wilson; Christopher Lee; Patrick Flood; Robert Langenbach; Jau-Shyong Hong Journal: Toxicol Appl Pharmacol Date: 2009-05-03 Impact factor: 4.219
Authors: Irene V Bijnsdorp; Jaap van den Berg; Gitta K Kuipers; Laurine E Wedekind; Ben J Slotman; Johannes van Rijn; M Vincent M Lafleur; Peter Sminia Journal: J Neurooncol Date: 2007-04-20 Impact factor: 4.130
Authors: Javier Angulo; Pedro Cuevas; Begoña Cuevas; Mohammad El Youssef; Argentina Fernández; Eduardo Martínez-Salamanca; Rocío González-Corrochano; Guillermo Giménez-Gallego Journal: J Transl Med Date: 2015-02-01 Impact factor: 5.531